Efficacy and Safety of Rebamipide/Nizatidine in Erosive Gastritis
Study Overview
This study examines the effectiveness of a combination therapy using rebamipide and nizatidine compared to nizatidine alone in treating erosive gastritis.
Study Details
- Participants: 260 patients with erosive gastritis.
- Groups: One group received rebamipide/nizatidine, and the other received nizatidine only.
- Duration: Treatment lasted for 2 weeks.
Results
- Primary Outcome: The combination therapy showed a significant improvement in mucosal erosions (62.0% vs. 49.2% for nizatidine alone).
- Secondary Outcomes: Both groups effectively cured erosions and improved symptoms like bleeding and erythema.
- Safety: No adverse effects were reported from the treatments.
Conclusion
The combination of rebamipide and nizatidine is effective for treating erosive gastritis.
Practical Solutions and Value
Clinical trials are essential for developing safe treatments. Our platform, DocSym, integrates clinical standards and research, making it easier for healthcare providers to access vital information.
In today’s healthcare landscape, efficiency is key. Our mobile apps facilitate scheduling, treatment monitoring, and telemedicine, enhancing patient care management.
By leveraging AI, clinics can streamline operations, improve patient outcomes, and reduce paperwork. Discover more at aidevmd.com.
